Greets Echo (@GreetsEcho) header
Greets Echo (@GreetsEcho) profile picture

Information and comment on AIM companies offering potential value.

Joined June 2010
Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)Photo by Greets Echo (@GreetsEcho)
Hear from Dr. Karadimitris and Dr. Kronenberg in our recent KOL webinar event, discussing how #iNKTs could improve #ImmunoOncology. Register to watch the replay here to learn more: bit.ly/3IfdVwH
7
17
Greets Echo retweeted
$PRTG The timeline is far sooner for revenue generated from PORT-2&3, multi $billion revenue inbound Safety Data due for both in Dec 21 2022 will be transformational for all shareholders Only 2 of 5 drugs in their pipeline The same BOD spun off Biohaven, now an $8bn company
9
22
Greets Echo retweeted
$PRTG PORT-1 multiple phase 2 data read outs due 2-3 months +Invincible Trial early data ClinicalTrials.gov NCT03058289 NCT04781725 Word is Intensity IPO backed with Portage stake increase INT230-6 combo $BMY $MRK Results exceptional-kills cancer cells,Deal inevitable
1
18
2
30
Our #immunooncology programs incorporate technology to optimally engage the immune system to attack #cancer. Read more about how we are leveraging #iNKT therapy to address multiple cancer types: bit.ly/30igpIV
1
9
2
30
Today, the Portage team had the chance to ring the @Nasdaq opening bell at Times Square in New York City! What a great way to celebrate our Nasdaq listing under $PRTG and our work in #ImmunoOncology, including progress on our #iNKT programs, in 2021.
Greets Echo retweeted
I would encourage anyone who is looking at investment in any #oncology and #cancer biotech or leading Pharmeceutical company to listen to the interview with Ian Walters at Portage Biotech. This #iNKT technology with combination is going to revolutionise cancer treatments! $PRTG
#ICYMI: Check out our CEO Ian Walters in conversation with Neil Canavan discussing the science of iNKT cells and innovative #cancer treatment on the LifeSci Partners Benchtop Bios podcast. Listen here: spoti.fi/3Ai9Hih
Greets Echo retweeted
This man threw a pint of beer at me on the escalators at Liverpool St around 5:10pm today and ran away when security tried to stop him. Please RT and help me find this mf @TfL @BTP @metpoliceuk
65
1,369
36
869
Greets Echo retweeted
Play it safe ALWAYS double bag @ the service station 🤔🤨🤣 #PetrolShortages
#PetrolShortages Stop living in fear because you watched yet more scaremongering bullshit on the news "there is no fuel shortage in the UK" NO shortage of service stations open in my part of the world.
3
1
1
4
Harsh comment from one of my boys? Norwich supporters can count on one hand how many goals Ipswich scored last night.
3
Today we announced financial results for the quarter ended June 30, 2021. Read the press release: bit.ly/3gGnjwY $PRTG
6
4
21
Greets Echo retweeted
Time to research ⁦@PortageBiotech⁩ $PRTG New #cancer treatments using #iNKT to switch a tumour so it becomes treatable! Revolutionary technology!
4
20
Today, our CEO Dr. Ian Walters issued a corporate update in a letter to shareholders, highlighting clinical development and financing milestones that have positioned the company for accelerated development of innovative cancer treatments. Read more here: bit.ly/3ABHgMV
Portage Biotech CEO Interview Explains Why Company Poised To Break Higher In 2H 2021 (NASDAQ: PRTG) | Get News getnews.info/1147084/portage…
Greets Echo retweeted
Replying to @RichieKennett
I think the biggest bounce is coming from the Portage stock price in the next week or two. The market is yet to understand the value of Port 2. Successful clinical trials will revolutionise treatments: Kills the cancer cells Built in immunotherapy prevents it returning
6
18
Greets Echo retweeted
$PRTG PORT-1
1
5
12
$PRTG price target $100. Share price is a steal at the current level.
6